Opal-D Capsule is a combination pharmaceutical formulation containing Domperidone 10 mg and Omeprazole 20 mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related mucosal damage and promoting ulcer healing. The synergistic action of these agents addresses both the motility and acid secretion components of gastrointestinal dysfunction. Opal-D Capsule is typically administered orally, once daily before meals, with dosage adjustments based on clinical response and patient tolerance. It is contraindicated in patients with known hypersensitivity to either component and should be used cautiously in individuals with hepatic impairment or underlying cardiac conditions. Common adverse effects may include headache, dry mouth, abdominal cramps, and diarrhea. Patients are advised to consult healthcare providers before initiating therapy, especially if pregnant, lactating, or on concomitant medications to avoid potential drug interactions. Opal-D Capsule offers a comprehensive approach to managing acid-related and motility disorders, improving patient quality of life.